Logo

Roche NimbleGen, BioDiscovery to Team on CGH Analysis Tools

Jun 03, 2008
NEW YORK (GenomeWeb News) – Roche said today that its Roche NibleGen subsidiary has inked an alliance with Los Angeles-based BioDiscovery to offer a combination of products targeting comparative genomic hybridization.
 
The pact will combine new high-density, 2.1 million probe arrays from Roche NimbleGen with BioDiscovery’s Nexus Copy Number software foe use in whole-genome CGH analysis. Under the alliance, the firms will co-market and co-promote their products and services to scientists worldwide.
 
In addition, Roche NimbleGen said that the firm would present data generated from the arrays using Nexus software to researchers through a series of seminars.
 
Terms of the alliance were not disclosed.
 

Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.